StockStudio / Shutterstock.com
Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Pfizer, Anacor Pharmaceuticals, crisaborole, shares, mergers and acquisitions